delayadjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215
Introduction
Cancer is a major public health problem in the United States and many other parts of the world. One in 4 deaths in the United States is due to cancer. In this article, we provide the expected numbers of new cancer cases and deaths in 2013 nationally and by state, as well as an overview of current cancer statistics using data through 2009, including incidence, mortality, and survival rates and trends. We also estimate the total number of deaths averted as a result of the decline in cancer death rates since the early 1990s, and provide the actual reported numbers of deaths in 2009 by age for the 10 leading causes of death and the 5 leading cancer types.
Materials and Methods

Incidence and Mortality Data
Mortality data from 1930 to 2009 in the United States were obtained from the National Center for Health Statistics (NCHS). 1, 2 There are several sources for cancer incidence data. The Surveillance, Epidemiology, and End Results (SEER)
program of the National Cancer Institute reports long-term (beginning in 1973), high-quality, population-based incidence data covering up to 26% of the US population. Cancer incidence rates for long-term trends ), 5-year relative and causespecific survival rates (2002) (2003) (2004) (2005) (2006) (2007) (2008) , and estimations of the lifetime probability of developing cancer (2007-2009) were obtained from SEER registries. [3] [4] [5] [6] The North American Association of Central Cancer Registries (NAACCR) compiles and reports incidence data from 1995 onward for cancer registries that participate in the SEER program or the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR). Incidence data for state-level rates (2005) (2006) (2007) (2008) (2009) ), trends by race/ethnicity (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) , and estimated new cancer cases in 2013 were obtained from NAACCR. 7 Cancer cases were classified according to the International Classification of Diseases for Oncology. 8 All incidence and death rates are age-standardized to the 2000 US standard population and expressed per 100,000 persons. Cancer incidence rates in this report are delay-adjusted whenever possible in order to account for anticipated future corrections to registry data due to inherent delays and errors in case reporting. Delay-adjusted rates primarily affect the most recent years of data for cancers that are frequently diagnosed in outpatient settings (eg, melanoma, leukemia, and prostate) and provide a more accurate portrayal of the cancer burden in the most recent time period. 9 For example, melanoma incidence rates adjusted for delays in reporting are 14% higher than unadjusted rates in the most recent reporting year. Delay-adjusted rates are available for SEER registry data and were obtained from the National Cancer Institute. Incidence trends presented for the most recent 5 years (2005) (2006) (2007) (2008) (2009) ) are based on delay-adjusted rates from SEER 13 cancer registries. 4 Cancer Statistics, 2013
Projected Cancer Cases and Deaths in 2013
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because cancer registration is incomplete in some states. Furthermore, the most recent year for which incidence and mortality data are available lags 3 to 4 years behind the current year due to the time required for data collection, compilation, quality control, and dissemination. Therefore, we project the numbers of new cancer cases and We projected the number of new invasive cancer cases that will be diagnosed in 2013 (with the exception of urinary bladder, for which in situ cases are included) using a 2-step process that first estimates complete incidence counts by state during years for which observed data are available, and then projects these counts 4 years ahead for the United States overall and each state individually. 10 To estimate the numbers of new breast carcinoma in situ (female) and melanoma in situ cases in 2013, we first estimated the number of in situ cases occurring annually from 2000 through 2009 in the United States by applying the age-specific incidence rates in the 18 SEER areas to the corresponding US population estimates provided in SEER*Stat. 12 We then projected the total number of cases in 2013 based on the annual percent change from 2000 through 2009 generated by the joinpoint regression model. 13 We estimated the number of cancer deaths expected to occur in 2013 in the United States overall and in each state using the joinpoint regression model based on the actual numbers of cancer deaths from 1995 through 2009 at the state and national levels as reported to the NCHS. 1 For the complete details of this methodology, please refer to Chen et al. Cancer Statistics, 2013 Other Statistics
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The estimated numbers of cancer deaths averted in men and women due to the reduction in overall cancer death rates were calculated by applying the 5-year age-specific cancer death rates in the peak year for age-standardized cancer death rates (1990 in men and 1991 in women) to the corresponding age-specific populations in the subsequent years through 2009 to obtain the number of expected deaths in each calendar year if the death rates had not decreased. We then summed the difference between the number of expected and observed deaths in each age group and calendar year for men and women separately. Note: State estimates may not add to US total due to rounding and the exclusion of states with fewer than 50 deaths.
Selected Findings
Expected Numbers of New Cancer Cases Table 2 . Figure 1 indicates the most common cancers expected to occur in men and women in 2013. Among men, cancers of the prostate, lung and bronchus, and colorectum will account for about 50% of all newly diagnosed cancers; prostate cancer alone will account for 28% (238,590) of incident cases in men. The 3 most commonly diagnosed types of cancer among women in 2013 will be breast, lung and bronchus, and colorectum, accounting for 51% of estimated cancer cases in women. Breast cancer alone is expected to account for 29% (232,340) of all new cancer cases among women. Table 1 also shows the expected numbers of deaths from cancer projected for 2013. It is estimated that about 580,350 Americans will die from cancer this year, corresponding to almost 1600 deaths per day. Cancers of the lung and bronchus, prostate, and colorectum in men and cancers of the lung and bronchus, breast, and colorectum in women continue to be the most common causes of cancer death. These 4 cancers account for almost half (48%) of the total cancer deaths among men and women (Fig. 1) . In 2013, lung cancer is expected to account for 26% of all female cancer deaths and 28% of all male cancer deaths. Table 3 provides the estimated numbers of cancer deaths in 2013 by state for selected cancer sites. Cancer Statistics, 2013 Lifetime Probability of Developing Cancer
Expected Numbers of Cancer Deaths
The lifetime probability of being diagnosed with an invasive cancer is higher for men (45%) than for women (38%) ( Table 4) . However, because of the earlier median age at diagnosis for breast cancer compared with other major cancers, women have a slightly higher probability of developing cancer before age 60 years. These estimates are based on the average experience of the general population and may over-or underestimate individual risk because of differences in exposure (eg, smoking history) and/or genetic susceptibility.
Trends in Cancer Incidence
Figures 2 to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. While incidence rates are declining for most cancer sites, they are increasing among both men and women for melanoma of the skin and cancers of the liver and thyroid (Fig. 3 , Table 5 ). Table 5 shows incidence (delay-adjusted) and mortality trends for all cancers combined and for selected cancer sites based on joinpoint regression analysis. Joinpoint is a tool used to describe and quantify trends by fitting observed rates to lines connected at ''joinpoints'' where trends change in direction or magnitude. 13, 15 According to data from the SEER 13 cancer registries, incidence rates in the most recent 5 years (2005-2009) decreased in males by 0.6% per year and were stable in females (Table  5) . Incidence rates are decreasing for all 4 major cancer sites except female breast, for which rates remained relatively stable from 2005 to 2009 after decreasing by 2% per year from 1999 to 2005. Lung cancer incidence rates in women began declining in the late 1990s, more than a decade after the decline began in men. 6 Differences in lung cancer incidence patterns between men and women reflect historical differences in tobacco use; cigarette smoking prevalence peaked about 20 years later in women than in men. 16 Recent rapid declines in colorectal cancer incidence rates have largely been attributed to increases in screening that can detect and allow the removal of precancerous polyps. [17] [18] [19] Although joinpoint trend analysis shows that the incidence rate for prostate cancer declined steadily by 1.9% per year from 2000 to 2009, it is important to realize that annual rates fluctuate widely (Fig. 3) (Table 5) . Death rates peaked in men in 1990 (279.8 per 100,000), in women in 1991 (175.3 per 100,000), and overall in 1991 (215.1 per 100,000).
Trends in Cancer Mortality
Between 1990/1991 and 2009, cancer death rates decreased 24% in men, 16% in women, and 20% overall. Figure 6 shows that as a result of almost two decades of consistent declines in cancer death rates, about 1,177,300 cancer deaths were averted, 152,900 of these in 2009 alone. Death rates continue to decrease for the 4 major cancer sites (Figs. 4 and 5) . Over the past two decades of data, death rates have decreased from their peak by more than 30% for cancers of the colorectum, female breast, and male 
Recorded Number of Deaths From Cancer in 2009
A total of 2,437,163 deaths were recorded in the United States in 2009, 567,628 of these from cancer. 23 Cancer is the second leading cause of death, following heart disease, accounting for 23% of all deaths. However, within 20-year age groups, cancer is the leading cause of death among both men and women aged 40 to 79 years (Table 6) . Table 7 presents the numbers of deaths for all cancers combined and for the 5 most common sites for each 20-year age group. Among males, leukemia is the leading cause of cancer death among those aged younger than 40 years, while lung cancer ranks first among men aged 40 years and older. Among females, tumors of the brain and other nervous system are the leading cause of cancer death among children and adolescents (aged younger than 20 years), breast cancer ranks first among women aged 20 to 59 years, and lung cancer causes the most cancer deaths in those aged 60 years and older. Tables 8 and 9 depict cancer incidence and death rates for selected cancers by state. Lung cancer shows the largest geographic variation in cancer occurrence by far, reflecting the large historical and continuing differences in smoking prevalence among states. 20 For example, lung cancer incidence rates in Kentucky, which has historically had the highest smoking prevalence, are almost 4-fold higher than those in Utah, which has the lowest smoking prevalence (128 vs 34 cases per 100,000 men). In contrast, state variations for other cancer sites are smaller in both absolute and proportionate terms. For example, the breast cancer incidence rate in Connecticut, which has the highest rate (137 per 100,000 women), is only 28% higher than that in Arizona, which has the lowest The blue line represents the actual number of cancer deaths recorded in each year, and the red line represents the number of cancer deaths that would have been expected if cancer death rates had remained at their peak.
Regional Variations in Cancer Rates
rate (107 per 100,000 women). For cancers that can be detected by screening or other testing practices, such as those of the prostate, female breast, and colorectum, state variation in incidence rates reflects differences in the utilization of these tests as well as differences in disease occurrence. Cancer Occurrence by Race/Ethnicity
Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 10) . For all cancer sites combined, African American men have a 14% higher incidence rate and a 33% higher death rate than white men, whereas African American women have a 6% lower incidence rate but a 16% higher death rate than white women. Cancer incidence and death rates are higher among African American men than white men for every cancer site listed in Table 10 . Factors known to contribute to racial disparities in mortality vary by cancer site and include differences in exposure to underlying risk factors (eg, historical smoking prevalence for lung cancer), access to high-quality screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment. 24 The higher breast cancer incidence rate among whites compared to women of other racial or ethnic groups is thought to reflect a combination of factors that affect both diagnosis (ie, more prevalent mammography among white women) and underlying disease occurrence (eg, later age at first birth and greater use of menopausal hormone therapy among white women). 25 Cancer incidence and death rates are lower in other racial and ethnic groups than in whites and African Americans for all cancer sites combined and for the 4 most common cancer sites. However, incidence and death rates for cancers related to infectious agents, such as uterine cervix, stomach, and liver, are generally higher in minority populations than in whites. Stomach and liver cancer incidence and death rates are twice as high in Asian Americans/Pacific Islanders as in whites, reflecting an increased prevalence of chronic infection with Helicobacter pylori and hepatitis B virus in this population. 26 Kidney cancer incidence and death rates are the highest among American Indians/Alaskan Natives, which may reflect the high prevalence of obesity and smoking in this population. 27 Cancer incidence rates can only be adjusted for delayed reporting in whites and African Americans because the long-term incidence data required for delay adjustment are not available for other racial and ethnic groups. During the past 10 years of data (2000-2009), while incidence rates (unadjusted for delayed reporting) declined by 1% or more per year among men of all racial/ethnic groups except American Indians/Alaska Natives, among women only slight declines (0.2%-0.3% per year) occurred among non-Hispanic whites and Hispanics (Table 11 ). In contrast, cancer death rates declined by 1.5% or more per year among men and by 1.1% or more per year among women of all races/ ethnicities except American Indians/Alaska Natives, among whom rates were stable. Notably, the largest 
Cancer Survival
African Americans are less likely to survive cancer than whites. The 5-year relative survival is lower among African Americans for every stage of diagnosis for nearly every type of cancer (Fig. 7) . These disparities may result from inequalities in access to and receipt of quality health care and/or from differences in comorbidities. As shown in Figure 8 , African Americans are less likely than whites to be diagnosed with cancer at a localized stage, when treatment is usually less extensive and more successful. The extent to which factors other than stage at diagnosis contribute to the overall survival differential is unclear. 28 A study of Medicare-insured patients Rates are per 100,000 and age adjusted to the 2000 US standard population. showed that African Americans remain less likely than whites to receive standard cancer therapies for lung, breast, colorectal, and prostate cancers. 29 Some studies suggest that African Americans who receive cancer treatment and medical care similar to that of whites experience similar outcomes. 30 There have been notable improvements in survival over the past 3 decades for most cancers for both whites and African Americans (Table 12) *The standard error of the survival rate is between 5 and 10 percentage points. †The survival rate for carcinoma in situ of the urinary bladder is 96% for All Races, 97% for Whites, and 91% for African Americans.
The largest improvements in survival have been for leukemia and non-Hodgkin lymphoma, while cancers of the lung and pancreas have shown the least improvement.
Relative survival rates cannot be calculated for some minority populations because accurate life expectancies are not available. Comparison of cause-specific survival rates of cancer patients diagnosed from 2002 to 2008 in SEER registry areas of the United States indicate that all minority male populations have a greater probability than whites of dying from cancer within 5 years of diagnosis, although the difference is small for Hispanic men. 6 In contrast, among women, Asian Americans/Pacific Islanders (69.1%) and *The proportions of carcinoma in situ of the urinary bladder are 51% for All Races, 52% for Whites, and 37% for African Americans.
Stage categories do not sum to 100% because sufficient information is not available to assign a stage to all cancer cases.
Hispanics (67.2%) have the highest 5-year cause-specific survival, followed by whites (66.2%), American Indians/ Alaska Natives (60.6%), and African Americans (57.6%). Minority populations are generally more likely than nonHispanic whites to be diagnosed at a distant stage of disease for all 4 major cancer sites. 31 
Cancer in Children
Cancer is the second most common cause of death among children ages 1 to 14 years in the United States, surpassed only by accidents; 1,320 children died from cancer in 2009. 1 Leukemia accounts for almost one-third of all cancers (including benign brain tumors) diagnosed in 
Limitations
The projected numbers of new cancer cases and cancer deaths should be interpreted cautiously because these estimates are model-based and may vary considerably from year to year for reasons other than changes in cancer occurrence. For instance, estimates are affected by changes in method, which occur regularly as modeling techniques improve over time and cancer registration becomes more complete. In addition, not all changes in cancer trends can be captured by modeling techniques. For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. The data used for tracking cancer trends are age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER and/or NPCR. Nevertheless, the American Cancer Society projections of the numbers of new cancer cases and deaths provide a reasonably accurate estimate of the current cancer burden in the United States. Errors in reporting race/ethnicity in medical records and on death certificates may result in underestimates of cancer incidence and mortality rates in nonwhite and nonAfrican American populations. It is also important to note that cancer data in the United States are primarily reported for broad racial and ethnic minority groups that are not homogenous, and thus important differences in the cancer burden within racial/ethnic subgroups are masked.
Conclusions
In 2009, Americans had a 20% lower risk of death from cancer than in 1991, when cancer death rates peaked. Despite this substantial progress, all demographic groups have not benefitted equally, particularly for cancers such as colorectal and breast, for which mortality declines have been attributed to earlier detection and improvements in treatment. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket as well as other disadvantaged populations. n
